BiotechTube

Abemaciclib + Letrozole

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Low Grade Serous Ovarian Carcinoma

Conditions

Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor

Trial Timeline

Nov 30, 2023 → Jan 1, 2028

NCT ID
NCT05872204

About Abemaciclib + Letrozole

Abemaciclib + Letrozole is a phase 2 stage product being developed by Eli Lilly for Low Grade Serous Ovarian Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05872204. Target conditions include Low Grade Serous Ovarian Carcinoma, Adult Type Granulosa Cell Tumor.

What happened to similar drugs?

0 of 7 similar drugs in Low Grade Serous Ovarian Carcinoma were approved

Approved (0) Terminated (1) Active (6)
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄Remestemcel-LMesoblastPhase 3
🔄remestemcel-LMesoblastPhase 3
🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05872204Phase 2Recruiting
NCT04393285Phase 2Active

Competing Products

20 competing products in Low Grade Serous Ovarian Carcinoma

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
azenosertibZentalis PharmaceuticalsPhase 2
32
Sepantronium BromideCothera BiosciencePhase 2
29
DS-1001bDaiichi SankyoPhase 2
39
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
Pirtobrutinib + MosunetuzumabEli LillyPhase 2
42
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
Mirvetuximab SoravtansineAbbViePhase 2
42
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
42
Efineptakin alfa + PembrolizumabMerckPhase 2
42
PembrolizumabMerckPhase 2
39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + DocetaxelMerckPhase 2
35
CilengitideMerckPhase 2
31
AvelumabMerckPhase 2
35
Human Papillomavirus vaccineMerckPhase 2
35